Rozainanee Mohd Zain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rozainanee Mohd Zain has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Amir Muhaimin Akmal Shukri
Institute of Medical Molecular Biotechnology (IMMB), Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh, Malaysia
1 shared publication - Fadzilah Mohd Nor
Department of Medical Microbiology & Parasitology, Faculty of Medicine, Universiti Teknologi MARA, Jalan Hospital
1 shared publication - Huan-Keat Chan
Clinical Research Centre, Sultanah Bahiyah Hospital, Alor Setar, Malaysia
1 shared publication - Jeyanthi Suppiah
Virology Unit, Infectious Disease Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, Malaysia
1 shared publication - Marimuthu Citartan
Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia, Bertam, 13200, Kepala Batas, Penang, Malaysia
1 shared publication - Muhammad Radzi Abu Hassan
Clinical Research Center, Hospital Sultanah Bahiyah, Jalan Langgar, Alor Setar 05460, Malaysia
1 shared publication
Latest Publications
- Open Access
- 29 August 2025
- Published by Springer Nature in Virology Journal
- Vol. 22 (1) , 1-11
Aptamer as a therapeutic agent for dengue infections
Dengue virus (DENV) poses a significant global health burden, with current treatments being limited and primarily supportive. Aptamers are an emerging class of molecular recognition elements that are cheaper, less immunogenic and have no batch-to-batch variation as compared to antibodies. In light of their advantages, aptamers can potentially offer a novel approach to counteract DENV by targeting viral proteins or host factors essential for viral replication and pathogenesis. This review gleans the recent advancements in the development of aptamer-based therapeutic agents targeting dengue virus infection. The latest advancement on aptamers targeting specific dengue virus components such as capsid protein (C), envelope domain III (E3), and nonstructural proteins (NS); and their roles in inhibiting viral replication are highlighted. Although the development of aptamers as potential therapeutics for dengue infections is still in its early stages, based on their therapeutic potentiality, they hold immense potential for dengue viral treatment.
- 29 August 2025
- Published by Springer Nature in Virology Journal
- Vol. 22 (1) , 1-11
Open AccessAptamer as a therapeutic agent for dengue infections
Dengue virus (DENV) poses a significant global health burden, with current treatments being limited and primarily supportive. Aptamers are an emerging class of molecular recognition elements that are cheaper, less immunogenic and have no batch-to-batch variation as compared to antibodies. In light of their advantages, aptamers can potentially offer a novel approach to counteract DENV by targeting viral proteins or host factors essential for viral replication and pathogenesis. This review gleans the recent advancements in the development of aptamer-based therapeutic agents targeting dengue virus infection. The latest advancement on aptamers targeting specific dengue virus components such as capsid protein (C), envelope domain III (E3), and nonstructural proteins (NS); and their roles in inhibiting viral replication are highlighted. Although the development of aptamers as potential therapeutics for dengue infections is still in its early stages, based on their therapeutic potentiality, they hold immense potential for dengue viral treatment.
- Open Access
- 29 January 2020
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 27 (6) , 638-643
Find the Missing Millions: Malaysia’s experience with nationwide hepatitis C screening campaign in the general population
Approximately 2.5% of the Malaysian population is currently living with hepatitis C virus (HCV) infection. Yet, the public awareness of the disease is limited and under‐screening remains a major challenge. With the support of international non‐for‐profit organizations, the Ministry of Health in Malaysia recently launched a one‐week nationwide hepatitis C screening campaign in conjunction with the World Hepatitis Day. For the first time, the rapid diagnostic test (RDT) for HCV screening was introduced in public health institutions. This campaign involved 49 hospitals and 38 health clinics across the country, targeting the adult general population with unknown HCV infection status. Of the 11 382 participants undergoing the RDT, 1.9% were found to be positive for hepatitis C antibody (anti‐HCV) and were referred to on‐site medical departments or nearby hospitals for confirmatory testing and treatment. Men, the Malay ethnic group, intranasal and injection drug users and ex‐prisoners were shown to have higher odds of being positive for anti‐HCV. In addition to serving as a model to educate the general population about the disease, this campaign demonstrates the feasibility of decentralizing HCV screening, particularly by promoting the use of RDT, and linking the HCV‐infected patients to care in Malaysia.
- 29 January 2020
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 27 (6) , 638-643
Open AccessFind the Missing Millions: Malaysia’s experience with nationwide hepatitis C screening campaign in the general population
Approximately 2.5% of the Malaysian population is currently living with hepatitis C virus (HCV) infection. Yet, the public awareness of the disease is limited and under‐screening remains a major challenge. With the support of international non‐for‐profit organizations, the Ministry of Health in Malaysia recently launched a one‐week nationwide hepatitis C screening campaign in conjunction with the World Hepatitis Day. For the first time, the rapid diagnostic test (RDT) for HCV screening was introduced in public health institutions. This campaign involved 49 hospitals and 38 health clinics across the country, targeting the adult general population with unknown HCV infection status. Of the 11 382 participants undergoing the RDT, 1.9% were found to be positive for hepatitis C antibody (anti‐HCV) and were referred to on‐site medical departments or nearby hospitals for confirmatory testing and treatment. Men, the Malay ethnic group, intranasal and injection drug users and ex‐prisoners were shown to have higher odds of being positive for anti‐HCV. In addition to serving as a model to educate the general population about the disease, this campaign demonstrates the feasibility of decentralizing HCV screening, particularly by promoting the use of RDT, and linking the HCV‐infected patients to care in Malaysia.